A
A. A. Palmu
Researcher at National Institute for Health and Welfare
Publications - 10
Citations - 457
A. A. Palmu is an academic researcher from National Institute for Health and Welfare. The author has contributed to research in topics: Pneumococcal conjugate vaccine & Vaccine trial. The author has an hindex of 5, co-authored 10 publications receiving 360 citations. Previous affiliations of A. A. Palmu include National Institutes of Health.
Papers
More filters
Journal ArticleDOI
Otitis media and its consequences: beyond the earache
Anne Vergison,Ron Dagan,Adriano Arguedas,Jan Bonhoeffer,Robert Cohen,Ingeborg Dhooge,Alejandro Hoberman,Johannes G. Liese,Paola Marchisio,A. A. Palmu,G. Thomas Ray,Elisabeth A. M. Sanders,Eric A. F. Simões,Matti Uhari,Johan Van Eldere,Stephen I. Pelton +15 more
TL;DR: An international group of multidisciplinary experts on middle-ear and paediatric infections met to explore where consensus exists on the management of acute otitis media and to propose to clinicians and public health officials their views on the actions needed to be taken to reduce the disease burden and the microbial antibiotic resistance.
Journal ArticleDOI
Persistence of neutralizing antibodies a year after SARS-CoV-2 infection in humans.
Anu Haveri,Nina Ekström,Anna Solastie,Camilla Virta,Pamela Österlund,Elina Isosaari,Hanna Nohynek,A. A. Palmu,Merit Melin +8 more
TL;DR: In this article, the authors assessed the persistence of serum antibodies following WT SARS-CoV-2 infection at 8 and 13 months after diagnosis in 367 individuals and found that NAb against the WT virus persisted in 89% and S-IgG in 97% of subjects for at least 13 months.
Journal ArticleDOI
Vaccine effectiveness of the pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against clinically suspected invasive pneumococcal disease: a cluster-randomised trial
A. A. Palmu,Jukka Jokinen,Heta Nieminen,Ritva Syrjänen,Esa Ruokokoski,T. Puumalainen,Marta Moreira,Lode Schuerman,Dorota Borys,Terhi Kilpi +9 more
TL;DR: This vaccine-probe analysis is the first report showing the effect of pneumococcal conjugate vaccines on clinically suspected invasive pneumococal disease, which implies low sensitivity of the laboratory-based case definitions and subsequently higher public health effect of pneumonia conjugates.
Journal ArticleDOI
A pneumococcal conjugate vaccination programme reduced clinically suspected invasive disease in unvaccinated children.
TL;DR: The 10‐valent pneumococcal conjugate vaccine was introduced to the Finnish national vaccination programme for children born since June 2010 and the indirect herd protection impact of the programme was estimated.
Journal ArticleDOI
Effectiveness of pneumococcal Haemophilus influenzae protein D conjugate vaccine against pneumonia in children: A cluster-randomised trial.
Terhi Kilpi,Jukka Jokinen,T. Puumalainen,Heta Nieminen,Esa Ruokokoski,Hanna Rinta-Kokko,Magali Traskine,Patricia Lommel,Marta Moreira,Javier Ruiz-Guiñazú,Dorota Borys,Lode Schuerman,A. A. Palmu +12 more
TL;DR: In this article, a double-blind trial of 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against several outcomes is presented.